Why These 3 Nasdaq Stocks Were Glowing Green This Week
Despite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week. The tech-heavy Nasdaq Composite, for instance, edged higher by nearly 3% during the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence.
Among the best performers within the growth stock landscape this week were biopharmaceuticals. During the same period, the gene-editing pioneer CRISPR Therapeutics (NASDAQ: CRSP) saw its shares jump by a healthy 24.6%, shares of the central nervous system drug developer BioXcel Therapeutics (NASDAQ: BTAI) rose by 19.8%, and the equity price of the genetic medicine company Verve Therapeutics (NASDAQ: VERV) stormed higher by a noteworthy 11%.
Why were these biopharma stocks churning higher in this volatile market? CRISPR has been steadily marching northward in anticipation of a possible regulatory approval for its gene-edited blood disorder therapy exa-cel. Exa-cel is being co-developed with rare disease specialist Vertex Pharmaceuticals, which bodes well for the therapy's commercial ramp (assuming approval).
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
With 55 Buy predictions and 2 Sell predictions Vertex Pharmaceuticals Inc. is one of the favorites of our community.
However, we have a potential of -3.94% for Vertex Pharmaceuticals Inc. as the target price of 450 € is below the current price of 468.45 €.
